{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T21:10:09Z","timestamp":1759093809522,"version":"3.44.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ijcard.2022.04.035","type":"journal-article","created":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T11:09:50Z","timestamp":1650107390000},"page":"118-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Treatment of diabetes and heart failure: Facts and hopes"],"prefix":"10.1016","volume":"359","author":[{"given":"Manfredi","family":"Rizzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Cianflone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Maranta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2022.04.035_bb0005","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ijcard.2021.11.086","article-title":"Influence of diabetes mellitus interactions with cardiovascular risk factors on post-myocardial infarction heart failure hospitalizations","volume":"348","author":"Yandrapalli","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2022.04.035_bb0010","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12933-021-01344-0","article-title":"CAPTURE study investigators. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries","volume":"20","author":"Mosenzon","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ijcard.2022.04.035_bb0015","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/5584_2020_514","article-title":"Glycaemic control and vascular complications in diabetes mellitus type 2","volume":"1307","author":"Maranta","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ijcard.2022.04.035_bb0020","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/dom.13477","article-title":"Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes","volume":"21","author":"Dawwas","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ijcard.2022.04.035_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154843","article-title":"Incretin-based therapies in 2021 - current status and perspectives for the future","volume":"122","author":"Rizzo","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.ijcard.2022.04.035_bb0030","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ijcard.2021.05.050","article-title":"Cardiologist\u2019s approach to the diabetic patient: no further delay for a paradigm shift","volume":"338","author":"Maranta","year":"2021","journal-title":"Int. J. Cardiol."},{"issue":"4","key":"10.1016\/j.ijcard.2022.04.035_bb0035","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s13300-022-01226-y","article-title":"Effect of oral semaglutide on cardiovascular parameters and their mechanisms in patients with type 2 diabetes: rationale and design of the semaglutide anti-atherosclerotic mechanisms of action study (SAMAS)","volume":"13","author":"Jani\u0107","year":"2022","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.ijcard.2022.04.035_bb0040","article-title":"Adoption of the ADA\/EASD guidelines in 10 Eastern and Southern European countries: physician survey and good clinical practice recommendations from an international expert panel","volume":"172","author":"Cardio-Metabolic Academy Europe East","year":"2021","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ijcard.2022.04.035_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.810791","article-title":"Sodium-glucose cotransporter 2 inhibitors and heart failure: a bedside-to-bench journey","volume":"8","author":"Cappetta","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.ijcard.2022.04.035_bb0050","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejim.2021.03.020","article-title":"Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: a meta-analysis of randomized controlled trials","volume":"87","author":"Lu","year":"2021","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.ijcard.2022.04.035_bb0055","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12933-021-01400-9","article-title":"GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ijcard.2022.04.035_bb0060","first-page":"80","article-title":"Cardiologist and Diabetologist crosstalk in the era of cardiovascular outcome trials of novel glucose-lowering drugs","volume":"21","author":"Maranta","year":"2018","journal-title":"Int. J. Cardiol. Heart. Vasc."},{"key":"10.1016\/j.ijcard.2022.04.035_bb0065","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2022.04.035_bb0070","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes","volume":"76","author":"Das","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2022.04.035_bb0075","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021","volume":"44","author":"American Diabetes Association","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcard.2022.04.035_bb0080","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ijcard.2020.12.074","article-title":"Filling the gap between guidelines and real world in the cardiovascular approach to the diabetic patients: the need for a call to action","volume":"329","author":"Maranta","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2022.04.035_bb0085","doi-asserted-by":"crossref","first-page":"787761","DOI":"10.3389\/fcvm.2021.787761","article-title":"Promoting a syndemic approach for cardiometabolic disease management during COVID-19: the capisco international expert panel","volume":"8","author":"Al Mahmeed","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.ijcard.2022.04.035_bb0090","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jamainternmed.2020.2543","article-title":"Comparison of reported deaths from COVID-19 and increase in total mortality in Italy","volume":"180","author":"Rizzo","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.ijcard.2022.04.035_bb0095","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1080\/14740338.2021.1970744","article-title":"The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism","volume":"20","author":"Banerjee","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.ijcard.2022.04.035_bb0100","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1007\/s13300-021-01170-3","article-title":"Use of novel antidiabetic agents in patients with type 2 diabetes and COVID-19: a critical review","volume":"12","author":"Popovic","year":"2021","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.ijcard.2022.04.035_bb0105","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1089\/met.2020.0037","article-title":"Diabetes and the COVID-19 pandemic: how insights from recent experience might guide future management","volume":"18","author":"Stoian","year":"2020","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"10.1016\/j.ijcard.2022.04.035_bb0110","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/eurjpc\/zwaa080","article-title":"Delphi consensus recommendations on how to provide cardiovascular rehabilitation in the COVID-19 era","volume":"28","author":"Ambrosetti","year":"2021","journal-title":"Eur. J. Prev. Cardiol."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527322005496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527322005496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:56:40Z","timestamp":1759093000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527322005496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":22,"alternative-id":["S0167527322005496"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2022.04.035","relation":{},"ISSN":["0167-5273"],"issn-type":[{"type":"print","value":"0167-5273"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of diabetes and heart failure: Facts and hopes","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2022.04.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2021.11.086","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}